Marc Beer

Marc Beer is the Chairman of the Board for a company called LumeN XT, Inc. LumeNS is a surgical device company. This company has patented illumination designs that will help surgeons get to parts of a patient’s body more precisely and safely. LumeN xt is helping its customers with individualized and customizable solutions.


Marc Beer has a background of at least 25 years of experience in biotechnology, pharmaceuticals devices, and diagnostics. Marc is proud to be working with talented surgeons and engineers at LumeN XT. Marc believes that with more successful surgeries performed that have less invasive approaches, will increase LumeN XT platform.


Using illumination products is said to help enhance visualization, precision, and flexibility during operations. It is said to be a better option when it is compared to the traditional operations and techniques. LumeN XT also uses a heat reduction mechanism to improve surgical precision and safety.


Marc Beer has been successful in multiple startup companies and has been very profitable while doing so. In August of 2016, Marc Beer was founding Chairman and CEO of Renovia Inc. Marc founded Renovia with Ramon Iglesias and Yolanda Lorie. This women’s health startup was funded by money raised by Marc in the amount of $42M.


Renovia develops therapeutic and diagnostic devices to treat different pelvic floor diseases and disorders. Renovia’s mission is to discover and deliver the first digital therapeutic and diagnostic devices for women with these different diseases and disorders. The money that Marc helped raise will go toward developing and testing a few more products for Renovia improvements.


Marc was also Founding Chairman of a clinical-stage biopharmaceutical company called Minerva Neurosciences, Inc. Minerva focused on helping patients treat central nervous system diseases. Minerva also helped develop innovative therapeutic compounds for diseases like Schizophrenia, Parkinson’s Disease, as well as mood and depressive disorders. Learn more:


Marc was the CEO of ViaCell in April of 2000. ViaCell is a biotechnology company specializing in the development of umbilical cord blood stem cells, preservation of the cells and ultimately the collection of those cells. Marc helped ViaCell grow to over 300 employees and go public in 2005. While being a CEO at ViaCell, Marc was also a member of Erytech Pharma. Erytech Pharma is a publicly-traded biopharmaceutical company.


Marc has lots of experience and expertise and has held many different positions throughout his professional journey. Marc was also Vice President of Global Marketing for Genzyme. Mark held a variety of sales and marketing roles in pharmaceutical and diagnostic sectors. Marc was also a member of different councils and research committees throughout his leadership journey.